Sen. Bernie Sanders, Independent from Vermont, riled Democrats' surprise energy, healthcare, and tax deal as a "Vote-a-Rama" as the Senate prepped up a scenario of passing by a simple majority US President Joe Biden's Build, Better Back initiative to drop prices of prescription drugs and reduce inflation as modified by senate majority leader Chuck Schumer endorsing amendments by Joe Manchin and Krysten Sinema.
Biden's initiative hit a bump when fellow democrats Joe Manchin (D - West Virginia) and Krysten Sinema (D- Arizona) opposed it on grounds of a huge public spend and subsidising the drug prices by taxing the rich and wealthy.
They both patched up with sen majority leader Schumer after he accepted their amendments to the Biden act setting the pace for passage of the bill.
The new agreement, made in private between Manchin and Senate Majority Leader Chuck Schumer (D-NY), is undergoing a "Vote-a-Rama" in the Senate over the weekend, in which lawmakers have been able to propose amendments to the bill.
Sanders, who unsuccessfully proposed three amendments, voiced his concerns about the legislation in a speech from the Senate floor Saturday evening.
"I want to take a moment to say a few words about the so-called Inflation Reduction Act that we are debating this evening," the progressive Democrat said early in his 38-minute speech.
"And I say 'so-called,' by the way, because, according to the CBO and other economic organizations that study this bill, it will, in fact, have a minimal impact on inflation," Sanders was quoted by the media as saying.
Sanders once unsuccessfully contested the presidential race, it may be recalled on the support of the youth in America who backed him on his education reforms. .
Democrats have argued that the Manchin-approved deal would decrease inflation and not raise taxes on average people while still tackling parts of the party's energy, healthcare, and tax reform agendas.
Republicans have argued that the new bill will raise taxes on low-income people and cause a spike in inflation, even if temporarily. Sanders has become a vocal critic of the legislation in recent days.
The Vermont senator praised the bill Saturday for including provisions that would allow Medicare to negotiate prescription drug prices with the pharmaceutical industry but expressed frustration that the changes would not go into effect for four years, at which point only 10 drugs would be covered.
"If anybody thinks that as a result of this bill, we're going to see lower prices for Medicare, you are mistaken. It ain't going to happen next year, the year after, or the year after," he said in his floor remarks.
"And by the way, given the incredible power of the pharmaceutical industry, I would suspect even money that they will figure out a way to get around this provision if it takes four years to implement. So, this provision will have no impact on the prices for those Americans. Furthermore, this provision will have no impact on the prices for Americans who are not on Medicare."
Calling it an "incredibly tepid bill", Sanders also bemoaned the legislation's support for the fossil fuel industry, which he called "a slap in the face to the communities fighting to protect themselves from filthy fossil fuels".
--IANS
ashe/pgh
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app